Skip to content
10-Q

Quarterly Report

ABBOTT LABORATORIES ABT

0001628280-25-021090

← back to feed
Filed
Apr 30, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Mar 31, 2025 1.74B sh
Long Term Debt Q1 2025 · Mar 31, 2025 $12.74B
Long Term Debt Q1 2025 · Dec 31, 2024 $12.63B
Short Term Investments Q1 2025 · Mar 31, 2025 $312M
Short Term Investments Q1 2025 · Dec 31, 2024 $351M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $6.53B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $7.62B
Stockholders Equity Q1 2025 · Mar 31, 2025 $48.81B
Stockholders Equity Q1 2025 · Dec 31, 2024 $47.66B
Current Liabilities Q1 2025 · Mar 31, 2025 $13B
Current Liabilities Q1 2025 · Dec 31, 2024 $14.16B
Current Assets Q1 2025 · Mar 31, 2025 $23.15B
Current Assets Q1 2025 · Dec 31, 2024 $23.66B
Total Assets Q1 2025 · Mar 31, 2025 $81.45B
Total Assets Q1 2025 · Dec 31, 2024 $81.41B
Shares Diluted Q1 2025 · Mar 31, 2024 1.75B sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $226M
Dividends Paid Q1 2025 · Mar 31, 2024 $957M
Capex Q1 2025 · Mar 31, 2024 $398M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $1.03B
Eps Diluted Q1 2025 · Mar 31, 2024 $0.70
Eps Basic Q1 2025 · Mar 31, 2024 $0.70
Sga Expense Q1 2025 · Mar 31, 2024 $2.96B
Rd Expense Q1 2025 · Mar 31, 2024 $684M
Net Income Q1 2025 · Mar 31, 2024 $1.23B
Operating Income Q1 2025 · Mar 31, 2024 $1.39B
Cost Of Revenue Q1 2025 · Mar 31, 2024 $4.46B
Revenue Q1 2025 · Mar 31, 2024 $9.96B